资讯  教育  校园  房产  旅游  娱乐  科技  健康  财经  体育  消费  文史  书画  能源

  RSS 设为首页   加入收藏
首页 > 文传商讯 > 正文

GE HealthCare Announces Completion of Phase I Subject Recruitment in Early Clinical Development Prog

时间:2023-03-01 14:22:00  来源:文传商讯  作者:
 

Novel manganese-based macrocyclic Magnetic Resonance Imaging (MRI) agent could offer an alternative to gadolinium-based agents
Manganese is a trace element naturally occurring in, and efficiently eliminated from, the human body
The clinical trial program demonstrates GE HealthCare’s commitment to innovation in contrast media and to building a portfolio of MRI imaging agents to address radiologists’ needs for their patients

CHALFONT ST GILES, England--()--GE HealthCare has today announced, at the European Congress of Radiology (ECR) in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Typically, MRI agents – used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue – are gadolinium-based. This manganese-based agent could broaden GE HealthCare’s portfolio of MRI contrast agents available to radiologists, providing a potential alternative in light of perceived concerns relating to gadolinium retention.

The macrocyclic, extra-cellular – or general-purpose – manganese-based contrast agent has comparable relaxivity - the ability of a contrast agent to enhance signal intensity during an MRI scan - and is expected to be diagnostically similar to current gadolinium-based contrast agents (GBCAs). Unlike gadolinium, manganese is endogenous, meaning that it is a trace element that is naturally occurring in and efficiently eliminated from the body. Along with its magnetic properties, this makes a manganese-based agent a viable alternative to gadolinium. In addition, a non-gadolinium agent could help limit the potential impact of post-patient excreted gadolinium in the environment.

The clinical trial, based at the clinical research unit at the Oslo University Hospital, Rikshospitalet, Norway, and overseen by Lead Investigator, Hasse K. Zaré, aims to investigate the safety profile and how this injectable manganese contrast agent is eliminated from the body in healthy volunteers. Previous manganese-based MRI agents have been reliant on a ‘free manganese’ release mechanism for their imaging efficacy. This novel investigational agent is tightly bound to the chelate, in a macrocyclic cage-like structure, so it is rapidly eliminated from - rather than actively released into - the body.

Dr Paul Evans, Head of Global R&D at GE HealthCare’s Pharmaceutical Diagnostics unit, said: “For many years we’ve been committed to investing in, and bringing to market, products to help solve some of radiology’s biggest challenges and unmet needs. This manganese-based MRI agent is one of a number of novel agents we have at various stages of development in our innovation pipeline, all of which aim to give practitioners more choice in delivering precision care for their patients.”

GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. For more than 40 years, GE imaging agents have been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.

Follow us on FacebookLinkedInTwitter, and Insights for the latest news, or visit our website www.gehealthcare.com for more information.

Contacts

GE HealthCare Media:
Mathilde Bouscaillou
M +3364 700 8271
Mathilde.Bouscaillou@ge.com

GE HealthCare is innovating in contrast media (Photo: Business Wire)

 
 
 
上一篇:Microba推出新一代医疗保健检测产品
下一篇:Radisys利用运行于高通FSM 5G RAN平台上的先进FWA FR2 SA解决方案,实现了2Gbps以上的数据传输速率
 
 
 
 
推荐资讯
中国浓香白酒核心产区沉淀一杯出“大国浓香”五粮液
中国浓香白酒核心产区
电影《钢铁意志》今日全国公映 青年歌唱家汤非献唱主题曲
电影《钢铁意志》今日
长安马自达好不好 恩施消费者有话说
长安马自达好不好 恩施
年轻人的座驾 创酷RS恩施受追捧
年轻人的座驾 创酷RS恩
栏目更新
  • 2025年蓝色星球奖获奖名单公布
  • Papa Johns推出首款可颂披萨,让披萨爱好者
  • Horizon3.ai融资1亿美元以巩固其在自主安全
  • Capvidia通过支持QIF的NX软件扩展基于模型的
  • HistoSonics与剑桥大学在李嘉诚基金会捐赠支
  • IQM《2025年量子现状报告》:量子行业必须解
  • 芯原超低能耗NPU可为移动端大语言模型推理提
  • 芯原AI-ISP芯片定制方案助力客户智能手机量
  • 芯原可扩展的高性能GPGPU-AI计算IP赋能汽车
  • Medisca Secures Settlement With FlackTek
  • 栏目热门
  • RNA sequencing transformed: Oxford Nanop
  • Featurespace募得2500万英镑以推动国际增长
  • 众多知名大厨将云集东京,为期10个月的千载
  • Tigo推出具有增强光伏系统监控、设计布局和
  • 穆迪分析为CreditLens解决方案新增重要的自
  • DOCOMO将以OEM的方式为台湾FET提供相册服务
  • 新白皮书呼吁让车辆自动驾驶和安全驾驶辅助
  • 60家挑战赛获奖者蓄势待发,迎接2019年香港
  • Velodyne在NVIDIA DRIVE平台展示可实现丰富
  • 阿联酋大爱基金会2018年人道主义举措造福11
  •  
     

     
     
    网站声明 | 网站简介 | 网站导航 | 频道招商 | 联系方式 | 友情链接
    www.hlwang.net 华鲁网